Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Stiles

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Biomedical Instrumentation & Technology|October 27, 2005
A view from the trenches...cellular phone use in hospitalsDavid Stiles
Biomedical Instrumentation & Technology|May 27, 2005
A view from the trenchesDavid Stiles
Biomedical Instrumentation & Technology|January 14, 2012
The case against: a new name for the fieldDavid Stiles
BMC Genomics|August 22, 2007
A detailed transcript-level probe annotation reveals alternative splicing based microarray platform differencesJoseph C Lee, David Stiles, Jun Lu, et al.
Yeast (Chichester, England)|August 19, 2009
Microarray studies on the genes responsive to the addition of spermidine or spermine to a Saccharomyces cerevisiae spermidine synthase mutantManas K Chattopadhyay, Weiping Chen, George Poy, et al.
FEBS Letters|May 3, 2005
Long CGG-repeat tracts are toxic to human cells: implications for carriers of Fragile X premutation allelesVaishali Handa, Deena Goldwater, David Stiles, et al.
Annals of Clinical and Translational Neurology|April 1, 2025
Phase 1, First-In-Human, Single-/Multiple-Ascending Dose Study of Iluzanebart in Healthy VolunteersAndreas Meier, Spyros Papapetropoulos, Andrew Marsh, et al.
Investigative Ophthalmology & Visual Science|October 26, 2011
High-throughput retina-array for screening 93 genes involved in inherited retinal dystrophyJin Song, Nizar Smaoui, Radha Ayyagari, et al.
The Lancet. Respiratory Medicine|January 29, 2019
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 studyJohn J McNamara, Susanna A McColley, Gautham Marigowda, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 30, 2019
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosisSeth Walker, Patrick Flume, John McNamara, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Biomedical Instrumentation & Technology|October 27, 2005
A view from the trenches...cellular phone use in hospitalsDavid Stiles
Biomedical Instrumentation & Technology|May 27, 2005
A view from the trenchesDavid Stiles
Biomedical Instrumentation & Technology|January 14, 2012
The case against: a new name for the fieldDavid Stiles
BMC Genomics|August 22, 2007
A detailed transcript-level probe annotation reveals alternative splicing based microarray platform differencesJoseph C Lee, David Stiles, Jun Lu, et al.
Yeast (Chichester, England)|August 19, 2009
Microarray studies on the genes responsive to the addition of spermidine or spermine to a Saccharomyces cerevisiae spermidine synthase mutantManas K Chattopadhyay, Weiping Chen, George Poy, et al.
FEBS Letters|May 3, 2005
Long CGG-repeat tracts are toxic to human cells: implications for carriers of Fragile X premutation allelesVaishali Handa, Deena Goldwater, David Stiles, et al.
Annals of Clinical and Translational Neurology|April 1, 2025
Phase 1, First-In-Human, Single-/Multiple-Ascending Dose Study of Iluzanebart in Healthy VolunteersAndreas Meier, Spyros Papapetropoulos, Andrew Marsh, et al.
Investigative Ophthalmology & Visual Science|October 26, 2011
High-throughput retina-array for screening 93 genes involved in inherited retinal dystrophyJin Song, Nizar Smaoui, Radha Ayyagari, et al.
The Lancet. Respiratory Medicine|January 29, 2019
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 studyJohn J McNamara, Susanna A McColley, Gautham Marigowda, et al.
Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society|June 30, 2019
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosisSeth Walker, Patrick Flume, John McNamara, et al.
Pageof 1